TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial; Independent Data Safety Monitoring Board Advised Co. That Interim Analysis Of Overall Response Rate Could Not Be Conducted, As Data Were Not Sufficiently Mature To Conduct Analysis